Eptinezumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Migraine in Children
Conditions
Migraine in Children, Migraine
Trial Timeline
Aug 4, 2020 → Aug 21, 2023
NCT ID
NCT04537429About Eptinezumab
Eptinezumab is a phase 1 stage product being developed by Lundbeck for Migraine in Children. The current trial status is completed. This product is registered under clinical trial identifier NCT04537429. Target conditions include Migraine in Children, Migraine.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07035197 | Pre-clinical | Recruiting |
| NCT06701526 | Approved | Active |
| NCT06428838 | Phase 3 | Recruiting |
| NCT05164172 | Phase 3 | Recruiting |
| NCT05064371 | Phase 3 | Completed |
| NCT05064397 | Phase 3 | Completed |
| NCT05045781 | Phase 1 | Completed |
| NCT04537429 | Phase 1 | Completed |
Competing Products
20 competing products in Migraine in Children
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABP-450 | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 52 |
| lasmiditan 200 mg + Sumatriptan + matching placebo | Eli Lilly | Phase 1 | 33 |
| ABP-450 + Placebo | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 44 |
| Galcanezumab + Erenumab | Eli Lilly | Approved | 85 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| Galcanezumab + Rimegepant + Placebo + Placebo | Eli Lilly | Approved | 85 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan | Eli Lilly | Phase 3 | 77 |
| Galcanezumab Prefilled Syringe + Placebo | Eli Lilly | Phase 2 | 52 |
| Emgality 120 MG in 1 ML Prefilled Syringe | Eli Lilly | Approved | 85 |
| Galcanezumab | Eli Lilly | Pre-clinical | 23 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 2 | 52 |